Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE36.5000
- TODAY'S CHANGE (%)-0.7500 (-2.0134%)
- Bid / Lots36.4600/ 2
- Ask / Lots36.5800/ 2
- Open / Previous Close37.2200 / 37.2500
- Day Range
- 52 Week Range
- Volume61,219
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1453 | 37.22 |
| 09:34 ET | 300 | 37.17 |
| 09:38 ET | 200 | 37.02 |
| 09:48 ET | 300 | 36.77 |
| 09:52 ET | 450 | 36.97 |
| 09:56 ET | 600 | 37.05 |
| 09:57 ET | 100 | 37.055 |
| 09:59 ET | 100 | 37.15 |
| 10:01 ET | 200 | 37.115 |
| 10:03 ET | 900 | 37.2 |
| 10:06 ET | 307 | 37.05 |
| 10:08 ET | 124 | 37.08 |
| 10:14 ET | 505 | 37.37 |
| 10:17 ET | 182 | 37.38 |
| 10:19 ET | 100 | 37.2 |
| 10:21 ET | 100 | 37.295 |
| 10:28 ET | 113 | 37.21 |
| 10:30 ET | 100 | 37.295 |
| 10:39 ET | 200 | 37.265 |
| 10:42 ET | 306 | 37.12 |
| 10:51 ET | 1600 | 37.27 |
| 10:53 ET | 400 | 37.26 |
| 10:55 ET | 100 | 37.27 |
| 11:00 ET | 400 | 37.28 |
| 11:02 ET | 500 | 37.26 |
| 11:06 ET | 1266 | 37.175 |
| 11:08 ET | 5495 | 36.84 |
| 11:09 ET | 9580 | 36.88 |
| 11:11 ET | 400 | 36.79 |
| 11:13 ET | 400 | 36.56 |
| 11:15 ET | 300 | 36.59 |
| 11:18 ET | 2250 | 36.53 |
| 11:20 ET | 300 | 36.51 |
| 11:22 ET | 100 | 36.51 |
| 11:24 ET | 1008 | 36.47 |
| 11:26 ET | 2400 | 36.38 |
| 11:27 ET | 200 | 36.36 |
| 11:29 ET | 2002 | 36.38 |
| 11:31 ET | 1000 | 36.34 |
| 11:33 ET | 200 | 36.34 |
| 11:36 ET | 400 | 36.36 |
| 11:38 ET | 300 | 36.4 |
| 11:40 ET | 500 | 36.39 |
| 11:45 ET | 2588 | 36.5 |
| 11:47 ET | 336 | 36.58 |
| 11:49 ET | 100 | 36.54 |
| 11:54 ET | 100 | 36.53 |
| 11:56 ET | 100 | 36.52 |
| 12:03 ET | 500 | 36.5 |
| 12:05 ET | 100 | 36.5 |
Jun 5, 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
May 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.8B | -13.5x | --- |
Structure Therapeutics Inc | 2.7B | -20.5x | --- |
Geron Corp | 2.9B | -13.8x | --- |
SpringWorks Therapeutics Inc | 2.9B | -7.1x | --- |
MoonLake Immunotherapeutics | 2.6B | -53.6x | --- |
Biohaven Ltd | 3.0B | -4.9x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
